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Review article
Insulin-like growth factor binding protein (IGFBP)-3 has roles in modulating the effect of 
IGFs by binding to IGFs and inhibiting cell proliferation in an IGF-independent manner. 
Although recent studies have been reported that IGFBP-3 has also roles in metabolic 
regulation, their exact roles in adipose tissue are poorly understood. In this review, we 
summarized the studies about the biological roles in glucose and lipid metabolism. 
IGFBP-3 overexpression in transgenic mice suggested that IGFBP-3 results in glucose 
intolerance, and insulin resistance. IGFBP-3 knockout (KO) mice exhibited normal insulin 
level and glucose response after glucose challenge. More recent study in IGFBP-3 KO 
mice with a high-fat diet demonstrated that IGFBP-3 KO mice exhibited elevated fasting 
glucose and insulin, but normal response to glucose challenge, suggesting that IGFBP-3 
KO mice may induce insulin resistance even though preserved insulin sensitivity. In vitro 
and in vivo studies using 3T3-L1 adipocytes and rat, IGFBP-3 induced insulin resistance 
by inhibiting glucose uptake. In contrast, the reduced levels of IGFBP-3 in obesity 
might induce insulin resistance by suppression of IGFBP-3’s anti-inflammatory function, 
suggesting IGFBP-3 has a protective effect on insulin resistance. Also, proteolysis of 
IGFBP-3 might contribute to the insulin resistance in obesity and type 2 diabetes 
mellitus. In addition, IGFBP-3 inhibited adipocyte differentiation, suggesting IGFBP-3 may 
contribute to the insulin insensitivity. Taken together, it is not yet certain that IGFBP-3 has 
a protective effect or enhancing effect on insulin resistance, and more studies will be 
needed to clarify the roles of IGFBP-3 in metabolic regulation. 
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Insulin-like growth factor binding protein (IGFBP)-3 is the most abundant IGFBP in 
serum, and comprises 150-kDa ternary complex with insulin-like growth factor (IGF)-I and 
an acid labile subunit (ALS), thereby prolonging the half-life of IGF-I in circulation. The major 
function of IGFBP-3 has been proposed to involve IGF binding and modulate the diverse 
biological actions of the IGFs, such as cell proliferation, differentiation, an increase in metabolic 
activity, and cell survival by regulating their access to the IGF-I receptor1-3). Additionally, 
IGFBP-3 exhibits clear and distinct biological effects, including inhibition of cell proliferation 
and inducing apoptosis in various cell types in an IGF-independent manner4-8). Mechanisms 
for this IGF-independent actions of IGFBP-3 have been demonstrated that IGFBP-3 increases 
the ratio of proapoptotic to antiapoptotic proteins9), or activates the caspases involved in a 
death receptor-mediated pathway10) to induce apoptosis, and arrests cell cycle in G1/S phase to 
inhibit cell growth11).
Recently, issue about the possible role of IGFBP-3 in metabolic regulation has been raised. 
Apart from conventional concept indicating that IGFBP-3 was used to involve in meta-bolic 
regulation by modulating IGF bioavailability, several studies have been reported that IGFBP-3 
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may have metabolic role independent of the IGF axis. However, 
most part of the exact role of IGFBP-3 in glucose and lipid 
metabolism remains poorly understood. In this review, focus 
will be placed on the actions of IGFBP-3 in glucose and lipid 
metabolism.
IGFBP-3-overexpressing transgenic mice study
IGFBP-3 overexpression in transgenic (Tg) mice in early 
studies exhibited little effect on birth weight, litter size and 
body weight other than some selective effect on organ growth, 
such as spleen, liver and heart12,13). However, these studies were 
accomplished in conditions showing only modest increase of 
IGFBP-3 expression. Use of the mouse phosphoglycerate kinase 
I and the cytomegalovirus promoters to overexpress IGFBP-3 
more effectively demonstrated 4.9- to 7.7-fold increase in 
serum level of IGFBP-3, and resulted in modest intrauterine 
and postnatal growth retardation, probably because of reduced 
IGF-I bioavailability, and showed heavier liver and epididymal 
fat masses compared with wild-type (WT) mice14). This Tg 
mice also showed dramatic metabolic changes: increased levels 
of fasting glucose and insulin, increased response to a glucose 
challenge, attenuated hypoglycemic effects of insulin and IGF-I, 
and reduced uptake of 2-deoxyglucose in muscle and adipose 
tissue15). These data suggest that overexpression of IGFBP-3 
results in fasting hyperglycemia, glucose intolerance, and 
insulin resistance. However, we have to be cautious to interpret 
these data on the basis of the finding that environment by 
overexpression of IGFBP-3 in Tg mice may not be expected in 
real body.
IGFBP-3-knockout (KO) mice study
It has been reported that body weight of IGFBP-3 KO mice 
was indistinguishable from WT, demonstrating that pre-natal 
and post-natal growth was not affected by IGFBP-3 KO16). The 
response to a glucose challenge in IGFBP-3 KO mice was same 
as that in WT. However, IGFBP-3-4-5 triple KO mice showed 
lower glucose and higher insulin levels after glucose challenge 
compared with WT mice, indicating that IGFBP-3-4-5 triple 
KO mice have increased glucose uptake and enhanced glucose 
clearance. Another study performed phenotypic comparisons 
of controls and four mouse lines with genetic mutants: liver-
specific IGF-I deficiency (LID), ALS KO (ALSKO), IGFBP-3 
KO (BP3), and a triply deficient LID/ALSKO/BP3 line (LAB)17). 
This study demonstrated that LID and LAB mice showed 
increased levels of serum insulin, probably due to increases 
in growth hormone (GH) and secondary insulin resistance. 
ALSKO mice exhibited increased glucose clearance on glucose 
tolerance test, reflecting increase of β-cell function and insulin 
sensitivity, while LID and LAB mice showed reduced clearance. 
In contrast, IGFBP-3 KO mice exhibited normal insulin level 
and glucose response after glucose challenge. More recent 
study in IGFBP-3 KO mice with a high-fat diet demonstrated 
that IGFBP-3 KO mice exhibited heavier weight, decreased 
resting metabolic rate, and elevated fasting glucose and insulin 
levels18). However, IGFBP-3 KO mice had relatively normal 
glucose response after glucose challenge, and increased basal 
hepatic glucose production, but after insulin stimulation during 
hyperinsulinemic clamps, indicating that IGFBP-3 KO mice 
preserve insulin sensitivity despite evidence of increased basal 
glucose turnover. 
Data from several studies did not show solid and consistent 
findings about the effect of IGFBP-3 KO on glucose metabolism. 
This discrepancy may come from many compounding and 
complicated factors in these studies. For example, IGF system 
is comprised of IGFs, type I and II IGF receptors, IGFBPs, 
and IGFBP proteases, and is working in a very complicated 
ways affecting influences on each other. Moreover, the 
prevalence of IGF-I complexes composing with IGF-I, ALS, 
and IGFBPs in serum and/or in tissues produces different 
effects on GH secretion and carbohydrate metabolism. Also, 
there is a possibility that changes in expression and bioactivity 
of IGFBP-3 in extrahepatic tissues can affect carbohydrate 
metabolism17). Moreover, each experiment was done in different 
conditions, such as diet (fasting, fed with normal chow, or fed 
high-fat diet), and age at the time of experiment. Nevertheless, it 
is of note that IGFBP-3 KO mice with a high-fat diet had heavier 
weight compared with WT and showed fasting hyperglycemia 
and hyperinsulinemia, indicating insulin resistance, even not in 
glucose tolerance test18). 
In vitro and in vivo study
It has been reported that IGFBP-3 may lead to insulin 
resistance in adipocytes19). In this report, IGFBP-3 reduced 
insulin-stimulated but not basal glucose uptake in 3T3-
L1 adipocytes independent of the IGF axis. IGFBP-3 also 
reduced insulin-stimulated glucose transporter-4 translo-
cation to the plasma membrane. This inhibitory effect 
of  IGFBP-3 was accomplished through the decrease in 
threonine phosphorylation of Akt, but not insulin receptor 
phosphorylation. Another study also reported that IGFBP-3 
induces insulin resistance in adipocytes in vitro  and in rats 
in vivo 20). Kim et al.20) reported that IGFBP-3 inhibits basal 
and insulin-stimulated glucose uptake in 3T3-L1 adipocytes 
through the decrease in insulin receptor phosphorylation, and 
proposed that a possible role for IGFBP-3 in cytokine-induced 
insulin resistance. They also demonstrated that infusion of 
IGFBP-3 to rats for 3 hours or 7 days inhibits peripheral glucose 
uptake and glycogen synthesis suggesting in vivo  effect of 
IGFBP-3. 
In contrast, a recent study reported that IGFBP-3 inhibits 
cytokine-induced insulin resistance and early manifestations of 
atherosclerosis21). Mohanraj et al.21) demonstrated that IGFBP-3 
inhibits tumor necrosis factor (TNF)-α-induced nuclear factor 
(NF)-κB activity in an IGF-independent manner, thereby 
restoring the deregulated insulin signaling and negating TNF-
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α-induced inhibition of glucose uptake. IGFBP-3 further 
inhibits TNF-α, C-reactive protein and high glucose-induced 
NF-κB activity in human aortic endothelial cells (HAECs) 
and subsequently suppresses monocyte adhesion to HAEC 
through the IGFBP-3 receptor. This study suggested that 
IGFBP-3 may have a distinct function in pathologic or disease 
state. This study also exhibited that IGFBP-3 dose not affect 
insulin-induced glucose uptake even under normal conditions. 
Another study showing that diet-induced obese rats exhibited 
a downregulation of IGFBP-3 expression in mesenteric fat 
suggests that IGFBP-3 may have a protective effect against 
obesity22).
IGFBP-3 may have a regulatory function on lipid meta-
bolism. Chan et al.23) reported that IGFBP-3 interferes with the 
peroxisome proliferator-activated receptor (PPAR)γ-dependent 
process of adipocyte differentiation and maintenance of the 
gene expression characteristic of mature adipocytes. These 
changes were associated with a decrease in lipid accumulation23) 
and adiponectin expression20) in cells treated with IGFBP-3 
during differentiation. Further, IGFBP-3 activates inhibitory 
Smad signaling in 3T3-L1 cells and that endogenous IGFBP-3 
modulates their adipogenic differentiation by regulating 
cell sensitivity towards the inhibitory effect of transforming 
growth factor-β24). Since adipocyte differentiation is required to 
mediate insulin sensitivity in adipocytes25), this inhibitory effect 
of IGFBP-3 on adipocyte differentiation may contribute to 
progression towards insulin resistance. In contrast, Grohmann et 
al.26) reported that IGFBP-3 as well as IGF-I stimulates glycerol-
3-phosphate dehydrogenase activity during differentiation 
of preadipocytes isolated from adipose tissue of children, 
indicating that IGFBP-3 enhances adipocyte differentiation. It is 
not yet determined whether IGFBP-3 can be either inhibitory or 
stimulatory to the cell differentiation according to the cell types 
or culture conditions, and the mechanisms of such a divergence 
of the IGFBP-3’s effect are poorly understood27).
Study about IGFBP-3 proteolysis 
Proteolysis of IGFBP-3 may contribute to the insulin resis-
tance of pregnancy, obesity, and type 2 diabetes mellitus. Yama-
naka et al.28) demonstrated that NH2-terminal fragment of 
IGFBP-3 binds insulin with high affinity and blocks insulin 
action by inhibiting autophosphorylation of the insulin receptor 
β subunit and phosphorylation of insulin receptor substrate-1. 
The conserved NH2-terminal and COOH-terminal sequences 
of IGFBP-3 and the appropriated ternary structures formed by 
disulfide bonds result in high affinity for IGFs but low affinity 
for insulin. When IGFBP-3 is reduced or fragmented, the 
insulin binding site at the NH2-terminus of IGFBP-3 is exposed, 
resulting in increased affinity for insulin and diminished affinity 
for IGFs28). Increased proteolysis of IGFBP-3 has been observed 
in serum from patients with type 2 diabetes mellitus29), and 
simple obesity21,30). Mohanraj et al.21) reported that proteolyzed 
IGFBP-3 positively correlates with adiposity parameters such 
as waist circumference, body mass index, fasting insulin, and 
insulin resistance index such as homeostasis model assessment 
of insulin resistance in overweight and obesity population. These 
studies suggest that increased proteolytic fragments of IGFBP-3 
in obese individuals probably induces insulin resistance by 
resulting in reduced serum levels of insulin thereby inhibiting 
insulin action, and reduced levels of intact IGFBP-3 thereby 
inhibiting its IGF-independent anti-inflammatory functions. 
Conclusions
There is a line of evidence that IGFBP-3 plays an important 
role in glucose and lipid metabolism. However, previous studies 
about the roles of IGFBP-3 in metabolic regulation did not 
provide convincing evidence. It is not yet certain that IGFBP-3 
has a protective effect or enhancing effect on inducing insulin 
resistance. Further, the mechanism of the effect of IGFBP-3 
in regulating metabolism has to be elucidated. More clinical, 
epidemiological, and biochemical studies will be needed to 
clarify the roles of IGFBP-3 in glucose and lipid metabolism.  
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